Professor

Zhanfeng Cui BSc MSc PhD DSc FREng CEng MIPEM CSci FIChemE

DavidPollock Professor of Chemical Engineering

Director, CRMI Technology Centre

Founding Director, Oxford Suzhou Centre for Advanced Research (OSCAR)

  • Biography
  • Research

Biography

2000-Present: Donald Pollock Professor of Chemical Engineering, Oxford University

2000-Present: Fellow of Hertford College, Oxford

Oct. 1999 - 2000: Reader in Engineering Science, Oxford University

Oct. 1994 - Sept 2000: Fellow and Engineering Tutor, Keble College, Oxford

Oct. 1994 - Sept 1999: University Lecturer in Engineering Science, Oxford University

March 1991 - Sept 1994: Lecturer, Department of Chemical Engineering, University of Edinburgh

May. 1990 - Feb. 1991: Research Fellow, Department of Pharmacy, University of Strathclyde

Oct.1988 - April 1990: Research Associate, Bioengineering Unit, University of Strathclyde, UK

DSc, 2009, University of Oxford

MA, 1994, Keble College, Oxford

PhD in Chemical Engineering,1987, Dalian University of Technology (China)

MSc in Chemical Engineering, 1984, Dalian University of Technology (China)

BSc in Chemical Engineering, 1982, Inner Mongolia Polytechnic University (China)

Other Roles

Zhanfeng is also Editor in Chief of the Bio-Design and Manufacturing journal.

He is Academic Founder of Oxford MEStar Limited (a spin-out company specialising in translational and regenerative medicine) and CN BioInnovation Limited,one of the pre-eminent Organ-on-Chip firms.

Research Interests

  • Regenerative Medical Engineering and Technologies
  • Bioprocessing and stem cell technology

Current Projects

The CRMI Technology Centre and Oxford Centre for Tissue Engineering and Bioprocessing develop translational and enabling technologies for tissue engineering and stem cell and cell therapies. This is thanks to a £9m centre grant sponsored by China Regenerative Medicine International, a public company listed on the Hong Kong Stock Exchange. It currently has around 35 researchers working on technologies for neural regeneration, diabetics, cancer immunotherapy and 3D bioprinting and biomanufacture.